image credit: Unsplash

Belite Bio Announces Positive Results from Phase 1 Clinical Trials of LBS-008

July 20, 2020

Via: BioSpace

Belite Bio, LLC, a clinical-stage biotech company, today announced positive results from two Phase 1 clinical trials in the United States and Australia for LBS-008, a First-in-Class oral small molecule Retinol Binding Protein 4 (RBP4) specific antagonist aimed to treat atrophic Age-related Macular Degeneration (Dry AMD) and Stargardt disease, an inherited juvenile form of macular degeneration.

LBS-008 Phase 1 Trial Results

A total of 83 subjects were administered with LBS-008 either as a single dose or repeated doses for 14 consecutive days. Both studies concluded that pharmacological doses of LBS-008 were well tolerated and that LBS-008’s PK / PD profile supports daily oral administration. Moreover, LBS-008 achieved potentially therapeutic-level target engagement.

Read More on BioSpace